Singapore, Nov. 5 -- Cerecin, a global healthcare company focused on developing brain health solutions and therapeutics for patients around the world, on 4 Nov 2019, announced the appointment of Bruce Morimoto as Vice President of Drug Development.

Based in the US, Bruce will be responsible for non-clinical drug development and translational medicine for Cerecin's existing products and future pipeline.

Bruce joins Cerecin's senior executive team with over 20 years' experience in research and development roles within leading institutions. Most recently, Bruce held the position of Vice President of Drug Development Operations with Alkahest Inc, a biopharmaceutical company targeting neurodegenerative and age-related diseases. In this role ...